These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma. Andrews MC; Turner N; Boyd J; Roberts AW; Grigg AP; Behren A; Cebon J Clin Cancer Res; 2015 Dec; 21(23):5222-34. PubMed ID: 26202951 [TBL] [Abstract][Full Text] [Related]
8. Targeting BRAF in melanoma: biological and clinical challenges. MandalĂ M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
9. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251 [TBL] [Abstract][Full Text] [Related]
10. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma. Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304 [TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway. Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403 [TBL] [Abstract][Full Text] [Related]
14. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. Cohen JV; Sullivan RJ Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297 [TBL] [Abstract][Full Text] [Related]